Form 4: Disc Medicine COO Receives Equity Grants

Disc Medicine's Chief Operating Officer, Jonathan Yen-Wen Yu, was granted 17,000 restricted stock units and options to purchase 25,500 shares.

Summary

• Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc. (IRON), was granted 17,000 Restricted Stock Units (RSUs) on February 10, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest annually in four 25% installments, beginning on February 15, 2027, contingent on continued service.
• Yu also received options to purchase 25,500 shares of Common Stock at an exercise price of $74.75 per share on February 10, 2026.
• These stock options will vest in 48 equal monthly installments, commencing on March 10, 2026, subject to continued service.
• The stock options have an expiration date of February 9, 2036.
• Following these transactions, Yu beneficially owns 57,555 shares of Common Stock (including RSUs) and 25,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at retention and performance alignment, without introducing new fundamental information about the company's operations or financial health.

Positives

• The equity grants align the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options promote executive retention over several years.

Future Outlook

The grants include multi-year vesting schedules, indicating an expectation of continued service from the Chief Operating Officer and a long-term incentive structure for executive performance.

Industry Context

StockSavvy.ai notes that equity grants, such as RSUs and stock options, are standard practice in the biotechnology and pharmaceutical industries for executive compensation. These grants are designed to attract, retain, and motivate key personnel by linking their financial incentives directly to the company's stock performance and long-term success. This particular filing reflects a routine compensation event for a senior executive.

Comparison to Industry Standards

• Equity compensation packages for Chief Operating Officers in the biotech sector typically include a mix of RSUs and stock options, similar to this grant. Companies like Moderna, BioNTech, and Regeneron frequently utilize such structures to incentivize leadership.
• The vesting periods (four years for RSUs and 48 months for options) are consistent with industry norms aimed at long-term retention and performance alignment, comparable to practices seen at companies such as Vertex Pharmaceuticals or Gilead Sciences.

Related Party Transactions

• The equity grants to Jonathan Yen-Wen Yu, Chief Operating Officer, constitute a related party transaction as they involve compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The grants represent a form of compensation that could lead to minor dilution upon vesting and exercise, but also serve to align executive interests with shareholder value creation.
• Employees: The grants demonstrate the company's commitment to incentivizing and retaining key leadership.

Next Steps

• The RSUs will begin vesting annually on February 15, 2027.
• The stock options will begin vesting monthly on March 10, 2026.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation in the form of equity grants. While these grants align management incentives with shareholder interests, they do not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this is a standard, expected disclosure.

Keywords

Disc Medicine, IRON, Form 4, insider transaction, equity grant, restricted stock units, stock options, executive compensation, Jonathan Yen-Wen Yu